Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting
NCT04799990 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2022-12-09
Summary
Study is not recruiting and using secondary data sources only
Conditions
Interventions
- DRUG
-
Subcutaneous Injection
- BIOLOGICAL
-
Comparator 1
Subcutaneous or Intravenous Injection
- DRUG
-
Comparator 2
Oral, Opthalmic, Subcutaneous or Intravenous Injection
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-23
- Primary Completion
- 2022-03-10
- Completion
- 2022-03-10
- FDA Drug
- Yes
More Related Trials
-
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
NCT03875482 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT03022045 ·Status: COMPLETED ·Phase: PHASE3
-
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT03000075 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
NCT04818385 ·Status: COMPLETED
-
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT03926169 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care
NCT04780516 ·Status: ACTIVE_NOT_RECRUITING
-
Risankizumab Long-term Remission Study
NCT04630652 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
NCT02672852 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
NCT04862286 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT02694523 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
NCT06333860 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
NCT04713592 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT03982394 ·Status: COMPLETED
-
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
NCT03671148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
NCT02719171 ·Status: COMPLETED ·Phase: PHASE2
-
Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation
NCT03518047 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
NCT03875508 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
NCT06764693 ·Status: RECRUITING
-
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
NCT04102007 ·Status: COMPLETED ·Phase: PHASE3
-
Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
NCT04722640 ·Status: UNKNOWN ·Phase: PHASE4
-
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
NCT03478787 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
NCT04433442 ·Status: COMPLETED
-
Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece
NCT06247319 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
NCT03047395 ·Status: COMPLETED ·Phase: PHASE3